Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

Exclusion Criteria

• •1. Synchronous and metachronous primary malignancies in but not limited to the upper aerodigestive tract, except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix.
• •2. Patients have undergone any type of anti-cancer treatment.
• •3. Baseline clinical stage M1 per AJCC 8th edition of staging classification, including supraclavicular lymph node metastases.
• •4. Investigators assessed major vessel involvement with high-risk hemorrhage.
• •5. A higher probability of esophageal perforation during conversion therapy.
• •6. Active infectious diseases, including but not limited to tuberculosis, hepatitis B virus, or hepatitis C virus.
• •7. Allergic to anti-cancer agents, including but not limited to anti-PD-1 or chemotherapy agents.
• •8. Given cardiopulmonary dysfunction, patients can not tolerate conversion therapy or surgery.
• •9. Pregnant or lactating women and women of childbearing potential who lacked effective contraception.